ERBB2 and triple-negative breast carcinoma: Among the 32 patients with negative conversion, 7 cases were the HER2-positive HR-negative before neoadjuvant treatment, 6 cases (18.75%) became triple negative breast cancer (TNBC) and 1 case (3.125%) became Luminal B after neoadjuvant treatment, and 25 cases were the HER2-positive HR-positive before neoadjuvant treatment.